Composition
| Ingredient | Strength |
|---|---|
| Glimepiride | 1 mg |
| Metformin Hydrochloride (sustained release) | 500 mg |
| Voglibose | 0.2 mg |
Therapeutic use
Used in the management of type 2 diabetes mellitus. Voglibose slows carbohydrate absorption in the gut, helping control blood sugar after meals.
For use under medical supervision only. Dosage, contraindications and precautions are as per the full prescribing information, available to registered medical practitioners on request.
Product details
- Brand name
- SUYGONE-MV1™
- Therapy range
- Diabetic
- Dosage form
- Uncoated bilayer tablet
- Pack size
- 10 x 10 tablets
- Number of ingredients
- 3
- Marketed by
- Grori Pharma Pvt Ltd
Frequently asked questions
What is the composition of Suygone-MV1?
Each unit of Suygone-MV1 contains Glimepiride 1 mg + Metformin Hydrochloride (sustained release) 500 mg + Voglibose 0.2 mg.
What is Suygone-MV1 used for?
Used in the management of type 2 diabetes mellitus. Voglibose slows carbohydrate absorption in the gut, helping control blood sugar after meals.
Who markets Suygone-MV1?
Suygone-MV1 is marketed by Grori Pharma Pvt Ltd, Hyderabad, as part of its Diabetic range.
How can I get product information or place an order for Suygone-MV1?
Doctors, pharmacies and distributors can call +91 95505 94814, +91 96528 45486 or +91 99669 45111, email groripharma@gmail.com, or use the enquiry form on the Grori Pharma contact page.